



Shareholder & Investor Update 50c funding round

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES EXCEPT TO CURRENT SHAREHOLDERS IN ACCORDANCE WITH RULE 135C OF THE US SECURITIES ACT

Vancouver, British Columbia, **August 31, 2016** – **PreveCeutical Medical Inc.** ("PreveCeutical", or the "Company"), a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers, announces final pre-public investment opportunity to accredited investors as well as and friends and family of all officers & directors of the company.

We are pleased to provide a short update to all our shareholders of record, accredited investors as well as friends and family of directors and officers of PreveCeutical who have expressed an interest in the Company.

As you know, we have been very busy putting the foundation in place to enable us to become the significant player in the fast emerging preventive health industry.

Our first step was securing the exclusive worldwide rights for Caribbean Blue Scorpion Venom on the 8th February 2016. Since then we have identified three major ways to monetize the asset. CELLB9 our homeopathic solution, Blue Scorpion Sports Beverages and our Immunotherapy Pre Clinical Program.

While working to monetize these sources we have brought together the best people in the business to create a world class team.

Further to this we have secured key partners who should enable us to capture a significant share of the markets we are addressing.

Currently our legal team is finalizing our preliminary prospectus to be filed with the BC Securities Commission in the near term as we gather the final required items.

If you would like the current Corporate Deck. Please email info@preveceutical.com

We are now pleased to announce the final pre-public investment opportunity to accredited investors as well as and friends and family of all officers & directors of the company.

This will be a Private Placement of up to \$5,000,000 CDN (\$3,500,000 USD) @ CDN \$ 0.50 per common share (USA\$ 0.35 per common share). The securities offered have not been or will not be registered under the US Securities Act and may not be offered absent registration or an exemption from registration.

Attached are the Canadian and US Subscription Agreements.

Thanks for your interest and support of the Company to date. We are really excited about the future prospects for our Company.

If you have any questions, please feel free to contact us.

FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Statements about the filing of the preliminary prospectus, the details of the Private Placement, any statement about the future performance of our management, and statements about the Company's future are all forward-looking information. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the preliminary prospectus if and when filed would meet the requirements of the reviewing regulatory body, the Private Placement will occur or that it will be completed on the terms described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.